Article
Allergy
Frederic J. de Blay, Alina Gherasim, Nathalie Domis, Pretty Meier, Furat Shawki, Claire Q. Wang, Jamie M. Orengo, Michelle DeVeaux, Divya Ramesh, Jessica J. Jalbert, Mohamed A. Kamal, Hisham Abdallah, Robert Dingman, Lorah Perlee, David. M. Weinreich, Gary Herman, George D. Yancopoulos, Meagan P. O'Brien
Summary: This study evaluated the efficacy of Fel d 1 monoclonal antibodies (REGN1908/1909) in preventing early asthmatic responses (EARs) induced by cat allergens in cat-allergic patients. The results showed that a single dose of REGN1908/1909 significantly prevented reductions in FEV1 and increased tolerance to allergen quantities.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Immunology
Glorismer Pena-Castellanos, Bryan R. E. Smith, Anna Pomes, Scott A. Smith, Maria A. Stigler, Hannah L. Widauer, Serge A. Versteeg, Ronald van Ree, Martin D. Chapman, Lorenz Aglas
Summary: This study investigated the biological activity of hIgE mAb derived from allergic donors on three allergens. The hIgE mAb showed effective induction of mediator release, high allergen specificity, and potential for standardization and mechanistic studies of IgE-mediated allergic diseases.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Allergy
Philippe Gevaert, Jarno De Craemer, Natalie De Ruyck, Sylvie Rottey, Jan de Hoon, Peter W. Hellings, Bram Volckaert, Kristof Lesneuck, Jamie M. Orengo, Amanda Atanasio, Mohamed A. Kamal, Hisham Abdallah, Vishal Kamat, Robert Dingman, Michelle DeVeaux, Divya Ramesh, Lorah Perlee, Claire Q. Wang, David M. Weinreich, Gary Herman, George D. Yancopoulos, Meagan P. O'Brien
Summary: This study tested the efficacy of a Bet v 1-specific antibody cocktail in birch-allergic subjects. The results showed that a single dose of REGN5713/14/15 significantly reduced nasal symptom scores caused by birch allergen challenge, and the reduction was sustained for up to 2 months. In addition, REGN5713/14/15 decreased basophil responsiveness to birch-related allergens.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Allergy
Joao Rodrigues Grilo, Claudia Kitzmueller, Lorenz Aglas, Gabriela Sanchez Acosta, Ute Vollmann, Christof Ebner, Fritz Horak, Tamar Kinaciyan, Christian Radauer, Fatima Ferreira, Beatrice Jahn-Schmid, Barbara Bohle
Summary: The use of recombinant Bet v 1 for sublingual immunotherapy induces cross-reactive IgG1 and IgG4 antibodies with varying reactivity. These antibodies exhibit highly variable cross-blocking activity to different allergens and show significant individual variance.
Article
Microbiology
Silvie Van den Hoecke, Marlies Ballegeer, Bram Vrancken, Lei Deng, R. Emma Job, Kenny Roose, Bert Schepens, Lien Van Hoecke, Philippe Lemey, Xavier Saelens
Summary: Treatment with M2e-specific monoclonal antibodies can significantly prolong survival of SCID mice and select for viruses with limited variation in M2e. However, some viruses may undergo an alternative escape route by acquiring mutations that result in delayed wild-type M2 expression, providing a mechanism of immune evasion that does not involve epitope alterations.
Review
Immunology
Qi Ke, Charles J. Kroger, Matthew Clark, Roland M. Tisch
Summary: Type 1 diabetes (T1D) is an autoimmune disease driven by T cells, and immunotherapies using monoclonal antibodies (mAb) can selectively reestablish beta cell-specific self-tolerance. mAb have varying efficacy in modulating autoimmunity and can alter the function of immune effector cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Hyeree Choi, Michelle Ho, Opeyemi S. Adeniji, Leila Giron, Devivasha Bordoloi, Abhijeet J. Kulkarni, Alfredo Perales Puchalt, Mohamed Abdel-Mohsen, Kar Muthumani
Summary: A panel of human anti-Siglec-9 hybridoma clones with high specificity and functionality were developed through immunizing mice with Siglec-9-encoding DNA and protein. The lead antibodies were found to enhance anti-tumor immune activity in vitro and significantly reduce tumor volume in an ovarian cancer humanized mouse model. These novel antibodies interfere with Siglec-9-mediated immunosuppression to augment anti-tumor immunity.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Frederik Peissert, Louis Pluss, Anna Maria Giudice, Tiziano Ongaro, Alessandra Villa, Abdullah Elsayed, Lisa Nadal, Sheila Dakhel Plaza, Luigi Scietti, Emanuele Puca, Roberto De Luca, Federico Forneris, Dario Neri
Summary: Programmed cell death protein 1 (PD-1) is an immunoregulatory target that can be targeted by different monoclonal antibodies for cancer therapy. In this study, researchers identified a new anti-PD-1 antibody with unique binding specificity and demonstrated its ability to block the interaction between PD-1 and PD-L1.
Editorial Material
Immunology
Judith Leitner, Claire Battin, Katharina Grabmeier-Pfistershammer, Peter Steinberger
Summary: This study demonstrates that depleting PD-1(+) T cells by blocking PD-1 antibodies can greatly impact the outcome of preclinical immunotherapy experiments. Different PD-1 antibodies may have varying effects on T cell activation and proliferation, with some potentially leading to significant loss of antigen-specific CD8 T cells.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2021)
Article
Immunology
Ann M. Carias, Jeffrey R. Schneider, Patrick Madden, Ramon Lorenzo-Redondo, Mariluz Arainga, Amarendra Pegu, Gianguido C. Cianci, Danijela Maric, Francois Villinger, John R. Mascola, Ronald S. Veazey, Thomas J. Hope
Summary: The study found that the delivery of antibodies to the vaginal mucosa following i.v. injection occurs in two phases, with the first phase involving delivery to the submucosa within 24 hours, and the second phase requiring approximately one week to saturate the stratified squamous epithelium.
JOURNAL OF IMMUNOLOGY
(2021)
Review
Allergy
Jennifer A. Dantzer, Edwin H. Kim, R. Sharon Chinthrajah, Robert A. Wood
Summary: The traditional approach for treating food allergies has been to avoid the offending food and use emergency medications if accidental exposures occur. However, the treatment landscape is evolving with the development of various approaches. This report discusses past, present, and future clinical trials for food allergy treatment, focusing on participant characteristics, protocol design, and study endpoints. It also provides recommendations for optimizing trial design and addressing unmet needs in this rapidly evolving field.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Rajesh Durairaj, Patrick Pageat, Cecile Bienboire-Frosini
Summary: In this study, the B-cell epitopes of Fel d 1 were predicted and the dynamics between epitopes and semiochemicals were explored using bioinformatics tools. The residue interactions of Fel d 1 with IgE were evaluated and the prominent epitope sites were predicted. Molecular dynamics simulation (MDS) was performed to evaluate the stability of the Fel d 1-ligand complex and decipher the effect of semiochemicals on Fel d 1 conformational epitopes. The ligand complexes showed significant fluctuation towards functionally exposed IgE-binding epitopes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Davide Busato, Monica Mossenta, Michele Dal Bo, Paolo Macor, Giuseppe Toffoli
Summary: Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, with low survival rates and a majority of patients already in advanced stages. Current treatment options for PDAC are limited, highlighting the need for targeted therapies that can differentiate between cancerous and non-cancerous cells. Antibody-based immunotherapies and antibody-conjugated nanoparticle-based targeted therapies, targeting specific tumor-associated antigens (TAA), show promise as potential innovative treatments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Health Care Sciences & Services
Sean Harrop, Chathuri Abeyakoon, Carrie Van der Weyden, H. Miles Prince
Summary: T-cell lymphomas, rare and unsatisfactorily treated, have shown progress in targeted therapies due to advancements in understanding T-cell lymphogenesis pathways and identifying therapeutic targets. New treatments include antibody-based, small molecule inhibitors, and immune-based therapies.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Multidisciplinary Sciences
Li-Jin Chan, Anugraha Gandhirajan, Lenore L. Carias, Melanie H. Dietrich, Oscar Vadas, Remy Visentin, Camila T. Franca, Sebastien Menant, Dominique Soldati-Favre, Ivo Mueller, Christopher L. King, Wai-Hong Tham
Summary: The study shows that antibodies against Plasmodium vivax RBP2b can provide protection against infection and disease, and inhibit invasion of reticulocytes. Researchers have identified different mechanisms by which human antibodies can inhibit the invasion ability of P. vivax RBP2b.
NATURE COMMUNICATIONS
(2021)
Review
Allergy
Oliver Pfaar, Jean Bousquet, Stephen R. Durham, Joerg Kleine-Tebbe, Mark Larche, Graham Roberts, Mohamed H. Shamji, Roy Gerth van Wijk
Summary: Over the past 110 years, allergen immunotherapy (AIT) has evolved as the most important pillar of the treatment of allergic patients, providing disease-modifying therapy with broad and undisputed clinical efficacy and safety evidence. Innovative approaches are continuously being developed to improve clinical improvement, with a focus on adjuvants, peptides, and new routes of administration.
Article
Allergy
Amanda Atanasio, Matthew C. Franklin, Vishal Kamat, Annabel Romero Hernandez, Ashok Badithe, Li-Hong Ben, Jennifer Jones, Joannie Bautista, George D. Yancopoulos, William Olson, Andrew J. Murphy, Matthew A. Sleeman, Jamie M. Orengo
Summary: This study demonstrates that a combination of mAbs targeting Bet v 1 can prevent the allergic response to birch pollen, highlighting the potential of allergen-specific antibody approaches in treating allergies.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Allergy
Marina Labella, Jose Antonio Cespedes, Inmaculada Dona, Mohamed H. Shamji, Ioana Agache, Cristobalina Mayorga, Maria Jose Torres
Summary: The real-world incidence of hypersensitivity reactions to the BNT162b2 mRNA COVID-19 vaccine was evaluated, and the basophil activation test (BAT) was found to have potential diagnostic value for confirming allergy to the PEG excipient. Positive BAT results to the vaccine may indicate a past COVID-19 infection rather than an allergy.
Article
Allergy
William H. Yang, Suzanne Kelly, Laura Haya, Rym Mehri, Divya Ramesh, Michelle DeVeaux, Claire Q. Wang, Pretty Meier, Sumit Narula, Furat Shawki, Ryan Pennington, Lorah Perlee, Meagan P. O'Brien
Summary: This study investigated the early and late asthmatic responses in cat-allergic mild asthmatics during cat allergen exposure in a naturalistic exposure chamber. The results showed that the average FEV1 change was not correlated with cat allergen levels, while the time to early asthmatic response and the incidence of early asthmatic response were highly correlated with cat allergen levels.
CLINICAL AND EXPERIMENTAL ALLERGY
(2022)
Review
Allergy
Mohamed H. Shamji, Hanisah Sharif, Janice A. Layhadi, Rongfei Zhu, Uday Kishore, Harald Renz
Summary: Allergen immunotherapy is an effective treatment for allergic rhinitis, inducing long-term clinical tolerance. Recent research has revealed that subcutaneous and sublingual immunotherapy induce immune tolerance through novel cell targets and molecular mechanisms, involving regulatory subsets of innate lymphoid cells and suppression of proinflammatory cells.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Mohamed A. Kamal, Yoko Franchetti, Ching-Ha Lai, Christine Xu, Claire Q. Wang, Allen R. Radin, Meagan P. O'Brien, Marcella Ruddy, John D. Davis
Summary: In the LIBERTY Grass AID trial, 16 weeks of treatment with dupilumab did not reduce nasal symptom scores in response to TG allergen challenge, but did improve tolerability of SCIT in patients with grass pollen-induced seasonal allergic rhinitis.
JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Allergy
Mariana Farraia, Ines Paciencia, Francisca Castro Mendes, Joao Cavaleiro Rufo, Mohamed H. Shamji, Ioana Agache, Andre Moreira
Summary: This study compared the cost-effectiveness of allergen immunotherapy (AIT) to standard treatment in children with allergic asthma. The results showed that AIT, especially when administered subcutaneously, was cost effective in reducing asthma exacerbations and medication use.
Review
Allergy
Mariana Farraia, Ines Paciencia, Francisca Castro Mendes, Joao Cavaleiro Rufo, Mohamed Shamji, Ioana Agache, Andre Moreira
Summary: This study aimed to assess the preventive role of allergen immunotherapy (AIT) in asthma onset. The findings suggest a potential preventive effect of AIT in asthma onset, particularly in children completing 3 years of therapy and in mono-sensitized patients.
Article
Allergy
Frederic J. de Blay, Alina Gherasim, Nathalie Domis, Pretty Meier, Furat Shawki, Claire Q. Wang, Jamie M. Orengo, Michelle DeVeaux, Divya Ramesh, Jessica J. Jalbert, Mohamed A. Kamal, Hisham Abdallah, Robert Dingman, Lorah Perlee, David. M. Weinreich, Gary Herman, George D. Yancopoulos, Meagan P. O'Brien
Summary: This study evaluated the efficacy of Fel d 1 monoclonal antibodies (REGN1908/1909) in preventing early asthmatic responses (EARs) induced by cat allergens in cat-allergic patients. The results showed that a single dose of REGN1908/1909 significantly prevented reductions in FEV1 and increased tolerance to allergen quantities.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Allergy
Mohamed H. Shamji, Markus Ollert, Ian M. Adcock, Oscar Bennett, Alberto Favaro, Roudin Sarama, Carmen Riggioni, Isabella Annesi-Maesano, Adnan Custovic, Sara Fontanella, Claudia Traidl-Hoffmann, Kari Nadeau, Lorenzo Cecchi, Magdalena Zemelka-Wiacek, Cezmi A. Akdis, Marek Jutel, Ioana Agache
Summary: Allergic diseases and asthma are closely connected to our living environment and patterns of exposure. The utilization of artificial intelligence and machine-learning methods can help unlock the potential of complex environmental data sets for understanding causality models of exposure and intervention. This article discusses the progress and future prospects of applying these approaches, as well as examples of machine learning in allergic disease research and its integration with representative exposome data. The promise of artificial intelligence in personalized medicine and improving public health is also explored.
Review
Allergy
Vanitha Sampath, Omar Shalakhti, Erika Veidis, Jo Ann Ifeoma Efobi, Mohamed H. Shamji, Ioana Agache, Chrysanthi Skevaki, Harald Renz, Kari C. Nadeau
Summary: Heat waves are becoming more intense, frequent, and long-lasting, causing significant heat stress on living organisms. This stress negatively impacts plants, animals, and humans, affecting various aspects of their functioning and leading to physiological and behavioral changes. This review summarizes the effects of heat stress on plants and animals and explores the adaptive mechanisms evolved to mitigate this stress.
Review
Allergy
Jean Bousquet, Mohamed H. Shamji, Josep M. Anto, Holger J. Schuenemann, G. Walter Canonica, Marek Jutel, Stefano Del Giacco, Torsten Zuberbier, Oliver Pfaar, Joao A. Fonseca, Bernardo Sousa-Pinto, Ludger Klimek, Wienczyslawa Czarlewski, Anna Bedbrook, Rita Amaral, Ignacio J. Ansotegui, Sinthia Bosnic-Anticevich, Fulvio Braido, Claudia Chaves Loureiro, Bilun Gemicioglu, Tari Haahtela, Marek Kulus, Piotr Kuna, Maciej Kupczyk, Paolo M. Matricardi, Frederico S. Regateiro, Boleslaw Samolinski, Mikhail Sofiev, Sanna Toppila-Salmi, Arunas Valiulis, Maria Teresa Ventura, Cristina Barbara, Karl C. Bergmann, Michael Bewick, Hubert Blain, Matteo Bonini, Louis-Philippe Boulet, Rodolphe Bourret, Guy Brusselle, Luisa Brussino, Roland Buhl, Victoria Cardona, Thomas Casale, Lorenzo Cecchi, Denis Charpin, Ivan Cherrez-Ojeda, Derek K. Chu, Cemal Cingi, Elisio M. Costa, Alvaro A. Cruz, Philippe Devillier, Stephanie Dramburg, Wytske J. Fokkens, Maia Gotua, Enrico Heffler, Zhanat Ispayeva, Juan Carlos Ivancevich, Guy Joos, Igor Kaidashev, Helga Kraxner, Violeta Kvedariene, Desiree E. Larenas-Linnemann, Daniel Laune, Olga Lourenco, Renaud Louis, Mika Makela, Michael Makris, Marcus Maurer, Erik Melen, Yann Micheli, Mario Morais-Almeida, Joaquim Mullol, Marek Niedoszytko, Robyn O'Hehir, Yoshitaka Okamoto, Heidi Olze, Nikolaos G. Papadopoulos, Alberto Papi, Vincenzo Patella, Benoit Petre, Nhan Pham-Thi, Francesca Puggioni, Santiago Quirce, Nicolas Roche, Philip W. Rouadi, Ana Sa-Sousa, Hironori Sagara, Joaquin Sastre, Nicola Scichilone, Aziz Sheikh, Milan Sova, Charlotte Suppli Ulrik, Luis Taborda-Barata, Ana Todo-Bom, Maria J. Torres, Ioanna Tsiligianni, Omar S. Usmani, Erkka Valovirta, Tuula Vasankari, Rafael Jose Vieira, Dana Wallace, Susan Waserman, Mihaela Zidarn, Arzu Yorgancioglu, Luo Zhang, Tomas Chivato, Markus Ollert
Summary: Biomarkers, especially digital biomarkers, are urgently needed in the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma. The lack of validated biomarkers in primary care poses a challenge, but the digital transformation of health care holds potential in improving allergy management. The Allergic Rhinitis and its Impact on Asthma (ARIA) and the European Academy of Allergy and Clinical Immunology (EAACI) have developed patient-reported outcome measures (PROMs) as digital biomarkers for rhinitis and asthma, including control biomarkers and quality-of-life biomarkers.
Article
Allergy
M. Pascal, S. M. Edelman, A. Nopp, C. Moebs, W. J. Geilenkeuser, E. F. Knol, D. G. Ebo, C. Mertens, M. H. Shamji, A. F. Santos, S. Patil, B. Eberlein, C. Mayorga, H. J. Hoffmann
Article
Allergy
Ralph Moesges, Christoph Zeyen, Esther Raskopf, Cengizhan Acikel, Hacer Sahin, Silke Allekotte, Mandy Cuevas, Mohamed H. Shamji, Jose Luis Subiza, Miguel Casanovas
Summary: The aim of this study was to determine the optimal dose of mannan-conjugated birch pollen allergoids for the treatment of birch pollen-induced allergies. The results showed that all doses of mannan-conjugated birch pollen allergoids were safe, with the highest dose of 10,000 mTU/mL demonstrating the greatest efficacy.
Article
Immunology
Hanisah Sharif, Hazim Ghani, Liyana Ahmad, Saifuddien Bagol, Justin Wong, Chee Wah Tan, Feng Zhu, Lin-Fa Wang, Lin Naing, Anne C. Cunningham
Summary: The study found that both homologous and heterologous booster doses can significantly increase neutralising antibody levels in individuals vaccinated with BBIBP-CorV. Additionally, there are differences in the duration of neutralising antibodies for mRNA vaccines, with mRNA-1273 showing longer persistence.